Intelligent Vaccine Enhancement System (IVES)

IVES integrates AI, IoT, blockchain, and nanomaterials to create a personalized vaccine administration system, enhancing immunogenicity and improving vaccine efficacy in elderly and immune-suppressed populations.

The original patent addresses the issue of poor vaccine efficacy in elderly and immune-suppressed populations by using saponins and agonists of the intracellular stimulator of interferon genes pathway. However, it lacks the ability to monitor and predict immune responses, secure vaccination records, and provide personalized insights. IVES solves these limitations by incorporating AI-powered analytics, IoT sensors, blockchain-based data storage, and nanomaterial-based adjuvants to create a more effective and efficient vaccine administration system.

IVES consists of four primary components: 1) a vaccine administration module, 2) an AI-powered analytics module, 3) an IoT sensor module, and 4) a blockchain-based data storage module. The AI-powered analytics module processes data from the IoT sensors, genomic data, and medical history to generate personalized insights and recommendations for enhancing immune responses. The blockchain-based data storage module securely stores vaccination records, AI-generated insights, and genomic data. The nanomaterial-based adjuvants are designed to target specific immune cells, enhancing the immune response. IVES can be used for various vaccine types, including influenza, and can be integrated into existing healthcare systems.

The new claims introduce the integration of AI, IoT, blockchain, and nanomaterials to create a personalized vaccine administration system, which is not present in the original patent. The inventive step lies in the synergistic combination of these technologies to enhance immunogenicity and improve vaccine efficacy.

IVES can be implemented in various ways, such as using different AI algorithms, IoT sensor configurations, or blockchain platforms. Additionally, IVES can be adapted for use in different populations, such as pediatric or immune-competent individuals, or for various vaccine types, including cancer or infectious disease vaccines.

IVES has significant commercial potential in the vaccine industry, particularly in the elderly and immune-suppressed populations. The system can be marketed to healthcare providers, pharmaceutical companies, and government agencies, offering a more effective and efficient vaccine administration system. The market potential is substantial, with the global vaccine market projected to reach $64 billion by 2027.